Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

What is Moderna Inc.?

Moderna (NASDAQ: MRNA) is a biotechnology company known for its development of vaccines, including the COVID-19 vaccine.

Why is Moderna Inc. going down?

MRNA stock is down 5.1% on Sep 18, 2024 15:41

• Moderna's stock saw a decrease despite Health Canada approving its updated COVID-19 vaccine.
• Negative comments from Jim Cramer about Moderna and his suggestion to focus on Pfizer could have impacted investor sentiment towards MRNA.
• The reminder of a securities class action by Rosen Law Firm may have further influenced the stock's decline.
• The increasing competition from Novavax in the COVID-19 vaccine market and its potential effects on Moderna's position possibly contributed to the bearish movement.

MRNA Price Chart

MRNA News

Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse - Moderna ( NASDAQ:MRNA )

On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Pfizer Inc. PFE and recommended buying more of the stock. On Sept. 16, Cantor Fitzgerald analyst Louise Chen reiterated Pfizer with an Overweight rating and maintained a $45 price target.

https://www.benzinga.com/trading-ideas/long-ideas/24/09/40917190/jim-cramer-labels-moderna-a-big-disappointment-but-suggests-doubling-down-on-another-pha

ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA - Moderna ( NASDAQ:MRNA )

NEW YORK, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. MRNA between January 18, 2023 and June 25, 2024, both dates inclusive ( the "Class Period" ) , of the important October 8, 2024 lead ...

https://www.benzinga.com/pressreleases/24/09/g40908823/rosen-a-leading-law-firm-encourages-moderna-inc-investors-to-secure-counsel-before-important-deadl

What's Going On With Moderna Shares Tuesday? - Moderna ( NASDAQ:MRNA )

Moderna, Inc. MRNA shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 vaccine. What Happened: Moderna announced on Tuesday that Health Canada approved its vaccine, SPIKEVAX, which aids in preventing COVID-19 in people six months of age ...

https://www.benzinga.com/news/24/09/40906114/whats-going-on-with-moderna-shares-tuesday

Why Novavax is Gaining Ground in COVID-19 Vaccine Race

Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.

https://www.zacks.com/commentary/2336754/why-novavax-is-gaining-ground-in-covid-19-vaccine-race

Moderna ( MRNA ) Rises Higher Than Market: Key Facts

The latest trading day saw Moderna (MRNA) settling at $69.17, representing a +1.3% change from its previous close.

https://www.zacks.com/stock/news/2336813/moderna-mrna-rises-higher-than-market-key-facts

Trending Today

Bittensor ($TAO) Crypto Forecast: Up 8.4% Today

Avalanche ($AVAX) Crypto Forecast: Up 5.1% Today

Sui ($SUI) Crypto Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Up 5.2% Today

Fantom ($FTM) Crypto Forecast: Down 5.1% Today

Bonk ($BONK) Crypto Forecast: Up 7.0% Today

Stox ($STX) Crypto Forecast: Up 10.3% Today

Aptos ($APT) Crypto Forecast: Up 12.4% Today

Ethereum ($ETH) Crypto Forecast: Up 5.8% Today

Fetch.ai ($FET) Crypto Forecast: Up 6.4% Today

Moderna Inc. Price History

18.08.2024 - MRNA Stock was down 5.1%

• Moderna's stock saw a decrease despite Health Canada approving its updated COVID-19 vaccine.
• Negative comments from Jim Cramer about Moderna and his suggestion to focus on Pfizer could have impacted investor sentiment towards MRNA.
• The reminder of a securities class action by Rosen Law Firm may have further influenced the stock's decline.
• The increasing competition from Novavax in the COVID-19 vaccine market and its potential effects on Moderna's position possibly contributed to the bearish movement.

22.07.2024 - MRNA Stock was down 5.2%

• An approval was granted for updated COVID-19 vaccines from Pfizer and Moderna, targeting the Omicron variant KP.2 strain of SARS-CoV-2. This development might have contributed to the bearish movement for Moderna as investors could have anticipated a more significant market impact from the approval.
• Concerns may have arisen among investors about the competitive landscape following the approval of the updated vaccines, as Novavax's shot did not receive FDA authorization, potentially impacting Moderna's market position.
• Market behavior could also be attributed to profit-taking by traders who were expecting a more positive response to the FDA approval news, thus prompting a sell-off in Moderna's stock.
• The bearish trend in Moderna's stock today likely stems from investors reassessing the potential market implications of the FDA approval in light of developments in the COVID-19 vaccine landscape.

22.07.2024 - MRNA Stock was down 5.1%

• The bearish movement in Moderna's stock today could be attributed to profit-taking by investors after a period of positive developments.
• Despite receiving FDA approval for an updated COVID-19 vaccine targeting the KP.2 variant, the market may have reacted negatively due to concerns about potential competition or market saturation.
• The bearish stance observed in Moderna's options trading could have influenced overall sentiment towards the stock, leading to a downward trend in its price.
• Investors might be waiting for more concrete updates from Moderna's upcoming Investor Event R&D Day and Business Updates before committing further to the stock, causing a temporary dip in its value.

22.07.2024 - MRNA Stock was down 5.0%

• Today's bearish movement in Moderna's stock (MRNA) can be attributed to the following factors:
• The announcement of an upcoming Investor Event and Business Updates may have raised concerns or uncertainties among investors, leading to a sell-off.
• The bearish stance taken by investors with significant capital, as indicated by options trading data, could have influenced market sentiment negatively.
• The ongoing securities class action lawsuits and reminders of lead plaintiff deadlines may have created legal uncertainties and investor unease, contributing to the downward pressure on the stock price.
• Overall, the combination of legal challenges and potential investor skepticism regarding future business developments might have fueled the bearish trend in Moderna's stock today.

03.08.2024 - MRNA Stock was down 5.1%

• Moderna's stock recently faced a decline, possibly influenced by profit-taking post an upward trend or uncertainties related to legal matters.
• The selling of company shares by Moderna's CFO and chief legal officer might have contributed to investor hesitancy and a pessimistic outlook on the stock.
• The FDA's approval of Novavax's updated COVID-19 vaccine could have shifted investor attention towards other vaccine choices, impacting Moderna's stock negatively.
• Taken together, the mix of profit-taking, insider selling, and increased competition within the vaccine market likely drove Moderna's downward trend today.

12.08.2024 - MRNA Stock was down 16.7%

• Moderna announced plans to cut $1.1 billion in costs and focus on launching 10 new products by 2027, indicating a strategic shift in its pipeline.
• Despite a positive CHMP opinion for its updated COVID-19 vaccine, the market reacted bearishly to the news, possibly due to concerns about the impact of deprioritizing certain products.
• The bullish options market dynamics with financial giants making notable moves may suggest conflicting sentiments among traders, with a slightly higher percentage leaning towards a bullish outlook.
• The combination of cost-cutting measures, product prioritization, and market dynamics could have contributed to the bearish movement in Moderna's stock price today.

12.08.2024 - MRNA Stock was down 12.6%

• Moderna unveiled its post-Covid strategy, which involved reducing research spending and projecting lower sales for 2025 than anticipated. This announcement likely influenced the recent decline in the stock price as investors may have doubts about the company's future growth.
• By slashing expenses and prioritizing specific pipeline projects, Moderna may have sparked concerns among investors regarding its sustainability and ability to innovate in the long term.
• Although there was bearish sentiment in the options market, with a notable percentage of traders taking a pessimistic stance, major financial institutions displayed confidence in Moderna by making bullish moves. This conflicting data could have contributed to the stock's volatility and downward trend.
• In conclusion, the combination of updated financial forecasts, cost reduction strategies, and diverse market sentiment likely played a role in the recent bearish performance of Moderna's stock.

12.08.2024 - MRNA Stock was down 14.0%

• Moderna's stock experienced a bearish movement today despite receiving a positive opinion from the Committee for Medicinal Products for Human Use for its updated COVID-19 vaccine, Spikevax.
• The bearish trend could be attributed to the company outlining a post-COVID roadmap that includes cutting research budgets and forecasting 2025 sales below expectations. Investors might be concerned about the impact of these decisions on the company's future growth prospects.
• Additionally, Moderna's decision to cut costs and deprioritize certain products in its pipeline could have contributed to the negative market sentiment, as investors may be uncertain about the company's long-term strategy and potential revenue streams.
• The bullish move in the options market, with financial giants showing confidence in Moderna, suggests a mixed sentiment among traders, with some remaining optimistic about the company's future despite the recent developments.

17.08.2024 - MRNA Stock was up 5.3%

• The strong upward movement in Moderna's stock could be linked to buoyant market sentiment arising from the company's continuous advancements in the COVID-19 vaccine race.
• The emergence of Novavax as a key player in the vaccine industry might have indirectly impacted Moderna positively, showcasing a favorable outlook for the sector overall.
• Although there were initial concerns raised by the DeSantis Administration regarding mRNA vaccines like Moderna's for vulnerable populations, the market appears to have dismissed these worries and instead focused on the company's recent achievements and potential.
• Investors seem optimistic about Moderna's future prospects, particularly given the company's distinct product offerings and ongoing collaborations, which have stimulated increased purchasing interest and propelled the stock price upwards.

09.08.2024 - MRNA Stock was up 5.0%

• Moderna (MRNA) witnessed significant upward movement in market trading today.
• The favorable CHMP opinion regarding Moderna's updated COVID-19 vaccine, Spikevax, likely played a role in the positive market trend.
• Reports of substantial investments from experienced investors in MRNA options, alongside contrary bearish viewpoints, may reflect a strong belief in the company's future potential.
• Market participants appear hopeful about Moderna's prospects within the biotechnology industry, particularly in light of its ongoing contributions to combating COVID-19.

09.08.2024 - MRNA Stock was up 5.7%

• Moderna's stock (MRNA) witnessed a notable increase in value today.
• The favorable CHMP opinion on Moderna's updated COVID-19 vaccine, Spikevax, likely contributed to the positive market sentiment.
• Despite some pessimistic wagers in the options market, the overall market conditions, particularly buoyed by the favorable updates on its COVID-19 vaccine, drove the stock price up.
• The significant buying activity from financial institutions in support of Moderna and the endorsement for marketing authorization of its updated COVID-19 vaccine may have instilled confidence in investors, driving the upward momentum in the market.

15.07.2024 - MRNA Stock was up 5.3%

• Despite facing multiple class-action lawsuits and allegations of misleading investors regarding the efficacy of its RSV vaccine, Moderna (MRNA) experienced a strong bullish movement in the market today.
• Investors might be optimistic about the company's future prospects, potentially driven by positive developments in its pipeline or overall market sentiment towards the biotech sector.
• The legal challenges and investigations seem to have had a limited impact on Moderna's stock performance, indicating that investors are focusing more on the company's innovation and growth potential.
• This divergence between legal troubles and market performance could suggest that investors have confidence in Moderna's ability to navigate these challenges and continue its trajectory of success in the biopharmaceutical industry.